What is SciTech Development?
SciTech Development is a clinical-stage specialty pharmaceutical company dedicated to enhancing cancer therapies. At the core of its innovation is the SciTech Drug Delivery Platform (SDP), a proprietary system designed to improve the bioavailability and safety of anticancer drugs. The company's lead candidate, ST-001 nanoFenretinide, leverages this platform to deliver fenretinide more effectively. SciTech Development is actively seeking strategic partnerships and further investment to propel its lead product through crucial clinical trials, aiming to overcome existing challenges with drug bioavailability and offer improved treatment options for various cancer indications.
How much funding has SciTech Development raised?
SciTech Development has raised a total of $8.2M across 2 funding rounds:
Other Financing Round
$2.7M
Debt
$5.5M
Other Financing Round (2023): $2.7M with participation from National Foundation for Cancer Research and Storm Lake Capital
Debt (2025): $5.5M, investors not publicly disclosed
Key Investors in SciTech Development
National Foundation for Cancer Research
The National Foundation for Cancer Research is a nonprofit organization focused on funding innovative cancer research and finding cures. They support scientists working on groundbreaking discoveries in cancer treatment, detection, and prevention.
Storm Lake Capital
Storm Lake Capital is a value-based investment firm that partners with lower middle-market companies, offering flexible capital solutions and operational expertise to enhance long-term value through equity and debt investments.
What's next for SciTech Development?
The recent major strategic investment signals a pivotal phase for SciTech Development, likely enabling the acceleration of its clinical trial pipeline for ST-001 nanoFenretinide. This capital infusion is expected to support the company's progression towards regulatory submissions and potential market entry. SciTech Development's focus on addressing bioavailability issues with its SDP positions it as a key player in the specialty pharmaceutical sector, with future growth contingent on successful clinical outcomes and strategic collaborations within the oncology space.
See full SciTech Development company page
